Intervacc receives order for Strangvac, a vaccine against the equine disease strangles, from the Dechra Pharmaceuticals PLC Group for launch in selected European countries
Stockholm, July 20th 2022 - Intervacc AB (publ) announces today that the company has received an order for the equivalent of approximately SEK 3 million from Dechra. The order concerns the delivery of Strangvac, a vaccine against the highly contagious and serious infectious disease equine strangles, which is endemic across Europe. The order, which contains vaccine vials for regions including the UK, Germany and France, is for delivery during July 2022 and used for launch in selected European countries. “This order from our distribution partner Dechra, will facilitate the launch of